Yousif Capital Management LLC grew its stake in shares of CVS Health Corporation (NYSE:CVS – Free Report) by 3.1% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 187,253 shares of the pharmacy operator’s stock after acquiring an additional 5,567 shares during the period. Yousif Capital Management LLC’s holdings in CVS Health were worth $16,046,000 as of its most recent SEC filing.
A number of other hedge funds have also modified their holdings of CVS. BlackRock Inc. acquired a new position in CVS Health in the 2nd quarter worth about $12,747,462,000. State Street Corp raised its stake in shares of CVS Health by 26.3% during the 2nd quarter. State Street Corp now owns 74,927,064 shares of the pharmacy operator’s stock worth $7,751,205,000 after purchasing an additional 15,604,883 shares in the last quarter. Wellington Management Group LLP lifted its holdings in shares of CVS Health by 49.8% during the 2nd quarter. Wellington Management Group LLP now owns 33,801,113 shares of the pharmacy operator’s stock valued at $3,496,725,000 after buying an additional 11,233,381 shares during the last quarter. Bank of America Corp DE lifted its holdings in shares of CVS Health by 148.0% during the 2nd quarter. Bank of America Corp DE now owns 23,188,670 shares of the pharmacy operator’s stock valued at $2,398,868,000 after buying an additional 13,836,701 shares during the last quarter. Finally, Pzena Investment Management LLC bought a new stake in shares of CVS Health in the 2nd quarter valued at approximately $1,217,558,000. 80.66% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
CVS has been the topic of several recent research reports. Weiss Ratings lowered shares of CVS Health from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Friday, October 9th. BMO Capital Markets set a $112.00 target price on shares of CVS Health in a research report on Wednesday, September 9th. Robert W. Baird set a $107.00 price target on shares of CVS Health in a research note on Thursday, August 6th. Leerink Partners cut their price target on shares of CVS Health from $119.00 to $112.00 and set an “outperform” rating on the stock in a report on Monday, October 12th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating on shares of CVS Health in a research note on Friday, October 9th. Twenty research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $107.80.
Get Our Latest Stock Analysis on CVS
CVS Health Stock Down 1.0%
Shares of NYSE CVS traded down $0.94 during mid-day trading on Friday, reaching $93.55. 4,601,538 shares of the company traded hands, compared to its average volume of 9,303,546. The company’s fifty day moving average is $91.60 and its two-hundred day moving average is $93.78. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.66 and a current ratio of 0.87. CVS Health Corporation has a fifty-two week low of $69.51 and a fifty-two week high of $110.68. The stock has a market cap of $119.64 billion, a PE ratio of 24.75, a price-to-earnings-growth ratio of 0.88 and a beta of 0.60.
CVS Health (NYSE:CVS – Get Free Report) last posted its earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share for the quarter, topping the consensus estimate of $1.87 by $0.71. The firm had revenue of $106.10 billion during the quarter, compared to analyst estimates of $100.03 billion. CVS Health had a return on equity of 13.12% and a net margin of 1.18%. The company’s revenue for the quarter was up 7.3% on a year-over-year basis. During the same period in the previous year, the company earned $1.81 EPS. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. On average, analysts expect that CVS Health Corporation will post 8.02 earnings per share for the current year.
CVS Health Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Monday, November 2nd. Investors of record on Thursday, October 22nd will be paid a $0.6650 dividend. The ex-dividend date is Thursday, October 22nd. This represents a $2.66 dividend on an annualized basis and a yield of 2.8%. CVS Health’s dividend payout ratio (DPR) is presently 70.37%.
CVS Health News Summary
Here are the key news stories impacting CVS Health this week:
- Positive Sentiment: Analyst price target maintained: Cantor Fitzgerald kept its $110 price target for CVS, implying confidence in further upside from recent trading levels. Cantor Fitzgerald maintains CVS price target
- Positive Sentiment: Expanded fall merchandise: CVS Pharmacy is adding collectibles, limited-edition products, beauty items, snacks and seasonal offerings across stores and CVS.com. The initiative could support front-store traffic and retail sales, although its financial impact is not yet quantified. CVS expands fall assortment
- Positive Sentiment: New clinic openings: CVS reportedly opened three clinics, supporting its broader healthcare-services strategy and potentially increasing patient engagement and revenue opportunities. CVS opens three clinics
- Neutral Sentiment: Unusually high call-option activity: Traders purchased 51,620 call options, about 203% above average. This signals increased speculative interest and may indicate bullish positioning, but options activity alone does not establish a change in CVS’s fundamentals.
- Neutral Sentiment: Analyst attention remains elevated: Zacks highlighted CVS as a heavily watched stock but did not provide a definitive new buy catalyst. Investors continue to weigh the company’s latest strong earnings performance against execution risks in its healthcare businesses. Zacks analysis of CVS
- Negative Sentiment: Recent underperformance: CVS previously declined even as the broader market gained, indicating lingering investor concerns or a lack of a fresh catalyst. The company’s strong latest quarterly results and fiscal 2026 earnings guidance provide support, but investors may remain focused on whether that performance is sustainable.
CVS Health Profile
CVS Health Corporation (NYSE: CVS) is a diversified health care company that provides pharmacy, insurance and health services in the United States. Its businesses serve consumers, employers, health plans and health care providers through pharmacies, benefit programs, insurance coverage and clinical care services.
The company’s Pharmacy Services segment, led by CVS Caremark, manages prescription drug benefits for employers, insurers and government programs. CVS Pharmacy operates retail pharmacies and health-focused stores that dispense prescriptions and offer over-the-counter products, health and wellness merchandise, immunizations and related services.
Featured Articles
- Five stocks we like better than CVS Health
- Why Western Digital’s AI Storage Boom Defies the Chip Sell-Off
- Grand Canyon Education Strengthens Its Outlook, But Wall Street Remains Divided
- Amex Stock Slides on Job Cuts, But the Real Story Is Macro
- Chefs’ Warehouse Has Rallied 76%—Can the Stock Keep Climbing?
Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corporation (NYSE:CVS – Free Report).
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.
